Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.68 |
| ▸ | DRD4 | P21917 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14100583 | 0.88 | SIGMAR1 (0.63) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL3164487 | 0.84 | SIGMAR1 (0.74) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL2425554 | 0.84 | SIGMAR1 (0.78) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL6500245 | 0.84 | SIGMAR1 (0.73) | SIGMAR1POLB | |
| Hydrochloric Acid SCHEMBL21410212 | 0.82 | SIGMAR1 (0.76) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL7144272 | 0.82 | SIGMAR1 (0.60) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL7268908 | 0.82 | SIGMAR1 (0.79) | SIGMAR1POLB | |
| SCHEMBL13102958 | 0.82 | SIGMAR1 (0.70) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL5230894 | 0.81 | SIGMAR1 (0.74) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL28996046 | 0.81 | SIGMAR1 (0.74) | SIGMAR1DRD4KMT2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190116-B1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-9999622-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-9937176-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20180092919-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3190116-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092919-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | JAK1, JAK2, JAK3 | SIGMAR1 2941/4885DRD4 2650/4885KMT2A 3230/4885 |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | JAK1, JAK2, JAK3 | SIGMAR1 2941/4885DRD4 2650/4885KMT2A 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.